FDA Roundup: March 22, 2024

This post was originally published on this siteSILVER SPRING, Md., March 22, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention)…

Continue Reading

Teamsters to Provide all U.S. Based Members access to Guaranteed Approved Income Protection Benefits through Union One

This post was originally published on this siteWASHINGTON, March 22, 2024 /PRNewswire/ — In a landmark initiative to enhance the financial security of its members, the International Union of Teamsters (“Teamsters” or “IBT”) has announced the launch of the IBT Voluntary Income Protection Plus (VIP+) Plan, underwritten by Prudential…

Continue Reading

2024 U.S. Celebration of World Standards Day to Highlight Standards for Climate Change Amidst “A Shared Vision for a Better World”

This post was originally published on this siteANSI and NIST Co-chair; NIBS Serves as 2024 Administrating Organization NEW YORK, March 22, 2024 /PRNewswire/ — Collaboration is the key to achieving shared goals. The U.S. standardization system has the greatest impact when all stakeholders work together. Particularly as our climate…

Continue Reading

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

This post was originally published on this site– The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) – Data show that ELAHERE treatment resulted in an overall…

Continue Reading